Active ingredients: eplerenone
What it is used for
Eplerenone is indicated to reduce the risk of: - cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 314 days of an acute myocardial infarction (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION). - cardiovascular mortality and morbidity in adult patients with NYHA Class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF = 30% or LVEF = 35% in addition to QRS duration of > 130 msec), in addition to standard optimal therapy (see CLINICAL TRIALS).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Yellow, round, biconvex film coated tablet, engraved with "E50" on one side
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on June 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient eplerenone
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems